Literature DB >> 33638118

CEA, CA 15-3, and miRNA expression as potential biomarkers in canine mammary tumors.

Mohit Jain1, Shailesh D Ingole2, Rahul S Deshmukh3, Simin V Bharucha1, Anagha S Nagvekar1, Rajiv V Gaikwad4, Shambhudeo D Kharde1.   

Abstract

The most often detected tumor in intact bitches is mammary tumors and represents a significant clinical problem throughout the world. Mammary neoplasms in canine have heterogeneous morphology, so the choice of the most appropriate biomarker is the biggest challenge in CMT detection. We performed a retrospective analysis and evaluated the canine cancer antigens and miRNA expression profiles as potential biomarkers. Sixty dogs based on histological examination divided into three groups, viz., dogs with a benign mammary tumor, malignant mammary tumor, and control/healthy. The CA 15-3 was found more sensitive than CEA but detection of both will increase sensitivity. miR-21 expression differed significantly in all three groups. miR-29b expression differed significantly between the control and benign group and control and malignant group. The miR-21 overexpression and miR-29b downregulation with CMT are associated with clinical stage and can be used as non-invasive diagnostic and prognostic biomarkers. Hence, evaluation of CA 15-3 along with CEA would be a non-invasive technique for detecting canine mammary tumors. Evaluation of deregulated circulating miR-21 could be a valuable prognostic marker for early detection of mammary tumors in canines while miR-29b can add sensitivity in the detection of the canine mammary tumors if evaluated with miR-21.

Entities:  

Keywords:  CA 15-3; CEA; canine; mammary tumor; miRNA

Year:  2021        PMID: 33638118     DOI: 10.1007/s10577-021-09652-7

Source DB:  PubMed          Journal:  Chromosome Res        ISSN: 0967-3849            Impact factor:   5.239


  55 in total

1.  Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.

Authors:  Sota Asaga; Christine Kuo; Tung Nguyen; Marilou Terpenning; Armando E Giuliano; Dave S B Hoon
Journal:  Clin Chem       Date:  2010-10-29       Impact factor: 8.327

2.  MicroRNA expression in canine mammary cancer.

Authors:  R Michelle Boggs; Zachary M Wright; Mark J Stickney; Weston W Porter; Keith E Murphy
Journal:  Mamm Genome       Date:  2008-07-30       Impact factor: 2.957

3.  Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.

Authors:  Dorit Di Gioia; Irene Blankenburg; Dorothea Nagel; Volker Heinemann; Petra Stieber
Journal:  Clin Chim Acta       Date:  2016-07-22       Impact factor: 3.786

4.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

5.  GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.

Authors:  Jonathan Chou; Jeffrey H Lin; Audrey Brenot; Jung-whan Kim; Sylvain Provot; Zena Werb
Journal:  Nat Cell Biol       Date:  2013-01-27       Impact factor: 28.824

6.  CA15.3, CEA and LDH in dogs with malignant mammary tumors.

Authors:  L C Campos; G E Lavalle; A Estrela-Lima; J C Melgaço de Faria; J E Guimarães; Á P Dutra; E Ferreira; L P de Sousa; É M L Rabelo; A F D Vieira da Costa; G D Cassali
Journal:  J Vet Intern Med       Date:  2012-11-01       Impact factor: 3.333

7.  EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours.

Authors:  Olga Bornachea; Mirentxu Santos; Ana Belén Martínez-Cruz; Ramón García-Escudero; Marta Dueñas; Clotilde Costa; Carmen Segrelles; Corina Lorz; Agueda Buitrago; Cristina Saiz-Ladera; Xabier Agirre; Teresa Grande; Beatriz Paradela; Antonio Maraver; José M Ariza; Felipe Prosper; Manuel Serrano; Montse Sánchez-Céspedes; Jesús M Paramio
Journal:  Sci Rep       Date:  2012-05-31       Impact factor: 4.379

8.  Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.

Authors:  Ileabett M Echevarría-Vargas; Fatma Valiyeva; Pablo E Vivas-Mejía
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

9.  MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours.

Authors:  Malgorzata Bulkowska; Agata Rybicka; Kerem Mert Senses; Katarzyna Ulewicz; Katarzyna Witt; Joanna Szymanska; Bartlomiej Taciak; Robert Klopfleisch; Eva Hellmén; Izabella Dolka; Ali O Gure; Joanna Mucha; Mariusz Mikow; Slawomir Gizinski; Magdalena Krol
Journal:  BMC Cancer       Date:  2017-11-07       Impact factor: 4.430

10.  Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer.

Authors:  Nan Dai; Xiao-Jing Cao; Meng-Xia Li; Yi Qing; Ling Liao; Xian-Feng Lu; Shi-Heng Zhang; Zheng Li; Yu-Xin Yang; Dong Wang
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more
  2 in total

1.  MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors.

Authors:  Eman S Ramadan; Noha Y Salem; Ibrahim A Emam; Naglaa A AbdElKader; Haithem A Farghali; Marwa S Khattab
Journal:  Vet Res Commun       Date:  2021-11-17       Impact factor: 2.459

Review 2.  Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.

Authors:  Patrícia Petroušková; Nikola Hudáková; Marcela Maloveská; Filip Humeník; Dasa Cizkova
Journal:  Life (Basel)       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.